GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avanos Medical Inc (NYSE:AVNS) » Definitions » Intrinsic Value: Projected FCF
中文

Avanos Medical (Avanos Medical) Intrinsic Value: Projected FCF

: $16.80 (As of Today)
View and export this data going back to 2014. Start your Free Trial

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-23), Avanos Medical's Intrinsic Value: Projected FCF is $16.80. The stock price of Avanos Medical is $18.76. Therefore, Avanos Medical's Price-to-Intrinsic-Value-Projected-FCF of today is 1.1.

The historical rank and industry rank for Avanos Medical's Intrinsic Value: Projected FCF or its related term are showing as below:

AVNS' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.11   Med: 1.37   Max: 2.29
Current: 1.12

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Avanos Medical was 2.29. The lowest was 1.11. And the median was 1.37.

AVNS's Price-to-Projected-FCF is ranked better than
67.06% of 343 companies
in the Medical Devices & Instruments industry
Industry Median: 1.67 vs AVNS: 1.12

Avanos Medical Intrinsic Value: Projected FCF Historical Data

The historical data trend for Avanos Medical's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avanos Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.56 20.01 20.33 19.96 16.80

Avanos Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.96 18.32 16.30 16.47 16.80

Competitive Comparison

For the Medical Devices subindustry, Avanos Medical's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avanos Medical Price-to-Projected-FCF Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Avanos Medical's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Avanos Medical's Price-to-Projected-FCF falls into.



Avanos Medical Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Avanos Medical's Free Cash Flow(6 year avg) = $-22.16.

Avanos Medical's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-22.16+1236.3*0.8)/46.300
=16.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avanos Medical  (NYSE:AVNS) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Avanos Medical's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=18.76/16.804946190787
=1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avanos Medical Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Avanos Medical's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Avanos Medical (Avanos Medical) Business Description

Traded in Other Exchanges
Address
5405 Windward Parkway, Suite 100 South, Alpharetta, GA, USA, 30004
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. The firm operates in one segment, medical devices, which primarily sells products related to pain management, IV Therapy, and respiratory and digestive health. The company divides its Medical Devices segment into two franchises: Pain Management and Chronic Care. Pain Management provides non-opioid products for acute and interventional pain, including cold and compression therapy. Chronic Care aims at addressing digestive and respiratory issues with feeding tubes and catheters. Avanos generates most of its revenue from its Chronic Care franchise and in North America.
Executives
Sudhakar Varshney officer: SVP, Global Supply Chain 5405 WINDWARD PARKWAY, SUITE 100 SOUTH, ALPHARETTA GA 30004
Lisa Egbuonu-davis director C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
John Joseph Hurley officer: Principal Accounting Officer 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
Patrick J Oleary director 31515 BALLANTYNE CORP, C/O SPX CORP, CHARLOTTE NC 28277
Mojirade James officer: SVP, General Counsel 5405 WINDWARD PKWY, ALPHARETTA GA 30004
Kerr Holbrook officer: SVP, GM Chronic Care 5405 WINDWARD PKWY, ALPHARETTA GA 30004
Michael Greiner officer: SVP - Chief Financial Officer C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421
David Edward Ball officer: SVP - Global Supply Chain AVANOS MEDICAL, INC., 5405 WINDWARD PKWY, ALPHARETTA GA 30004
William David Haydon officer: SVP, GM Pain Franchise 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
Arjun Ranjan Sarker officer: Senior VP, International HALYARD HEALTH, INC., 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
Gary Blackford director 7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Joseph Fralin Woody director, officer: Chief Executive Officer 5405 WINDWARD PARKWAY, SUITE 100 SOUTH, ALPHARETTA GA 30004
Steven E Voskuil officer: See Remarks 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
John W Wesley director 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
John Raymond Tushar officer: President, Global Franchises HALYARD HEALTH, INC., 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004